Pomalidomide combinations are a safe and effective option after daratumumab failure.

ABSTRACT:

Purpose

Outcomes of multiple myeloma (MM) patients who are refractory to daratumumab are dismal and no standard of treatment exists for this patients' population. Here, we investigate the role of pomalidomide combinations in daratumumab-refractory MM patients.

Methods

We performed a retrospective analysis of myeloma patients treated at four referral centers (three in Germany and one in Italy). Review chart identified 30 patients with relapsed and refractory myeloma, who progressed during treatment with daratumumab and were treated with pomalidomide-based combinations in the subsequent lines of therapy.

Results

Responses improved from 37% with daratumumab to 53% with pomalidomide. Of seven patients with extramedullary MM (EMM), four achieved a clinical stabilization wi

SUBMITTER: Brioli A 

PROVIDER: S-EPMC10356885 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature